Latest Breaking News On - Design therapeutics inc - Page 1 : comparemela.com

Design Therapeutics (NASDAQ:DSGN) Rating Increased to Overweight at Piper Sandler

Design Therapeutics (NASDAQ:DSGN) Rating Increased to Overweight at Piper Sandler
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJohnp schmidPiper sandlerHermes incSecurities exchange commissionRoyal bankNisa investment advisorsSimplicity wealthDesign therapeutics incBleakley financial groupDesign therapeuticsGet free reportDirector johnExchange commissionFire capitalInvestment advisors

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPratik shahUpcoming program milestonesExchange commissionDevelopment candidatesStrategic communicationsDesign therapeutics incDevelopment for fuchs endothelial corneal dystrophyTherapeutics announces first quarterHighlights upcoming programNew drug productFriedreich ataxiaToward clinicalFuchs endothelial corneal dystrophyObservational study currently enrolling patientsMyotonic dystrophy

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif., May 07, 2024 Design Therapeutics, Inc. , a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will.

New yorkUnited statesDesign therapeutics incStrategic communicationsMarkets healthcare conference

Design Therapeutics, Inc (NASDAQ:DSGN) Director Purchases $66,605 66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now directly owns […]

United statesJohnp schmidSecurities exchange commissionGroup plcNisa investment advisorsDesign therapeutics incTower research capitalRoyal bankDesign therapeutics company profileHermes incDesign therapeuticsGet free reportDirector johnExchange commissionFire capitalInvestment advisors

John P Schmid Acquires 9,156 Shares of Design Therapeutics, Inc (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now owns 9,156 […]

United statesJohnp schmidDesign therapeutics company profileTower research capitalSecurities exchange commissionHermes incGroup plcRoyal bankNisa investment advisorsDesign therapeutics incDesign therapeuticsGet free reportDirector johnExchange commissionFire capitalInvestment advisors